Swot Analysis Of Indian Pharmaceutical Industry

1412 Words6 Pages
EXECUTIVE SUMMARY: The report basically highlights on how the pharmaceutical industry of India works and its dynamics. The report also highlights about the Indian and global scenarios of pharmaceuticals industry and thereby comparison of those two. It comprises of analysing the industry by PEST, SWOT, PORTER’S five force model and HHI. It explains the current scenario of the industry in terms of growth and future outlook of the industry and opportunities. The Indian pharmaceutical industry has been growing rapidly at the rate of 8-9% every year as per our analysis. It stands in the 4th position in terms of volume and 13th in terms of values. The industry has been seeing the rapid growth in infrastructure, technology and various range of products. The demand for exports is also growing in the same passion due to the increase in the capability of production of medicines. The report also highlights the top 5 players in Indian pharmaceutical industry with their sales and revenue as well. • Cipla • Ranboxy • Dr.Reddy’s • Sun pharma • Aurobindo MAJOR PHARMACEUTICALS COMPANIES IN INDIA: COMPANY NAME NET SALES YEAR CIPLA 69.77 INR 2012-2013 Dr.REDDY’S 66.86 INR 2012-2013 RANBOXY 63.03 INR 2012-2013 AUROBINDO 42.84 INR 2012-2013 SUN PHARMA 40.15 INR 2012-2013 CIPLA: Cipla was established in the year 1935 and is known by the name “The chemical industrial and pharmaceutical laboratories”. The actual operations of the company started in 1937. The initial accumulated capital was 6 lakhs. The company is spread across various places in the country such as banglore, Mumbai, Goa and some other places. The company is known for its exporting as it exports to more than 150 countries all over the world and the major regions inc... ... middle of paper ... ...s the next best thing that can happen in the pharmaceutical industry. Increasing costs, expiring patents (both process and product), low R&D cost in the country and market dynamics are driving the MNCs to outsource both manufacturing and research activities. India with its pool of chemistry skills and low cost advantages, both in manufacturing and research included with skilled manpower will attract a large number of businesses in the future. There is lots of scope for growth. The Indian per capita consumption of drugs, stands at US 2.99 dollars, which is amongst the lowest in the world, as when compared to Japan- 415 us dollars, Germany-220 US dollars and USA- 189 US dollars. And studies show that this huge gap indicates the huge opportunities which can be uncovered by the industry. REFERENCES: http://indianresearchjournals.com/pdf/IJMFSMR/2013/May/4.pdf
Open Document